1. Home
  2. Search

Search

Search results

735 results found

Research

Page
My research program is rooted in clinically grounded, outcomes-driven investigation aimed at improving care for patients with pelvic floor disorders. Across projects, I focus on questions that arise directly from clinical practice, studying how surgical technique, perioperative care, and health...

BIDMC Glycomics Core Launches SUGA for Rapid N-Glycan Profiling

News: January 12, 2026
Many biologically critical proteins such as viral surface proteins (including SARS-CoV-2 spike), antibodies, and cell-surface receptors are heavily glycosylated, and these sugars can profoundly influence protein function, stability, immune recognition, and drug response. A new Journal of Proteome...

Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma.

Publication: Journal Article
Valvo, Veronica, Asumi Iesato, Taylor R Kavanagh, Carmen Priolo, Zsuzsanna Zsengeller, Alfredo Pontecorvi, Isaac E Stillman, Suzanne D Burke, Xiaowen Liu, and Carmelo Nucera. 2021. “Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma.”. Thyroid : Official Journal of the American Thyroid Association 31 (9): 1335-58.

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.

Publication: Journal Article
Antonello, Zeus A, Nancy Hsu, Manoj Bhasin, Giovanni Roti, Mukta Joshi, Paul Van Hummelen, Emily Ye, et al. 2017. “Vemurafenib-Resistance via de Novo RBM Genes Mutations and Chromosome 5 Aberrations Is Overcome by Combined Therapy With Palbociclib in Thyroid Carcinoma With BRAFV600E.”. Oncotarget 8 (49): 84743-60.